Cullinan director granted 25,319 stock options
Cullinan Therapeutics director Mary Thistle received a stock option grant covering 25,319 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cullinan Therapeutics director Mary Thistle received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was granted at no cost to her.
The award vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director on that date. Following this grant, she holds options for 25,319 underlying shares.
Insider Trade Summary
Grant/Award: 25,319 shares
Grant/Award
1 txn
Insider
Thistle Mary
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 25,319 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 25,319 contracts (Direct)
Footnotes (1)
- F1. The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Key Figures
Option grant size: 25,319 shares
Exercise price: $13.55 per share
Shares underlying option: 25,319 shares
+2 more
5 metrics
Option grant size
25,319 shares
Stock Option (Right to Buy) granted to director Mary Thistle
Exercise price
$13.55 per share
Conversion or exercise price of the stock option
Shares underlying option
25,319 shares
Common Stock underlying the derivative security
Post-grant option holdings
25,319 derivative shares
Total shares following transaction for this option award
Vesting date trigger
June 16, 2027
Full vesting or earlier on date of next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, vest in full, annual meeting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 13.5500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"which shall vest in full on the earlier of (i) June 16, 2027"
annual meeting financial
"or (ii) the date of the Issuer's next annual meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
continued service as a director financial
"subject to the Reporting Person's continued service as a director"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cullinan Therapeutics (CGEM) disclose about Mary Thistle’s latest Form 4?
Cullinan Therapeutics reported that director Mary Thistle received a stock option grant for 25,319 shares at a $13.55 exercise price. The options were granted at no cost and represent equity-based compensation tied to her board service.
How many stock options did Mary Thistle receive from Cullinan Therapeutics (CGEM)?
Mary Thistle was granted stock options covering 25,319 shares of Cullinan Therapeutics common stock. These options provide the right to buy that number of shares if exercised in the future in accordance with the grant’s terms.
What is the exercise price of Mary Thistle’s Cullinan Therapeutics (CGEM) option grant?
The grant to Mary Thistle carries an exercise price of $13.55 per share. This means she can purchase Cullinan Therapeutics common stock at $13.55 for each of the 25,319 shares underlying the option, once the award is fully vested and exercisable.
When do Mary Thistle’s Cullinan Therapeutics (CGEM) options vest?
The options granted to Mary Thistle vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting. Vesting is contingent on her continued service as a director through the applicable vesting date.
Is Mary Thistle’s Cullinan Therapeutics (CGEM) option grant tied to her director role?
Yes. The filing states the 25,319-share option vests only if Mary Thistle continues serving as a director through the vesting date. This links the equity award directly to her ongoing board service at Cullinan Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates